Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...
Like in other chronic inflammatory disorders, achieving disease activity control in SLE requires the application of the treat-to-target strategy. This approach requires setting clear treatment targets ...
Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...
In a new study, researchers identified eight disease activity domains for further development into the new Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE), a clinical trial ...
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive ...
Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...
Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Belimumab and rituximab demonstrated promise as potential treatments for both refractory and severe childhood systemic lupus erythematosus. Belimumab and rituximab demonstrated promise as potential ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback